However, the TGF-β1 staining of the metastatic lesion in 9 GC patients with PM who did not receive neoadjuvant treatment was significantly higher than that of the primary lesions (Fig. 7I), while the TGF-β1 staining of the remaining 21 patients who received neoadjuvant treatment still showed no difference in PCD levels (Fig. 7J). The gene discussed is TGFB1; the disease is gastric cancer.